Literature DB >> 23313516

A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months.

Marta Kubera1, Katarzyna Curzytek, Weronika Duda, Monika Leskiewicz, Agnieszka Basta-Kaim, Boguslawa Budziszewska, Adam Roman, Alena Zajicova, Vladimir Holan, Ewa Szczesny, Wladyslaw Lason, Michael Maes.   

Abstract

Chronic activation of immune-inflammatory and oxidative and nitrosative stress (O&NS) pathways plays an important role in the pathophysiology of clinical depression. Increased IgA responses directed against LPS of gram-negative bacteria, indicating increased bacterial translocation, may be one of the drivers underpinning these pathways. There is a strong association between signs of bacterial translocation and chronicity of depression and O&NS, but not pro-inflammatory cytokines. The aims of the present study were to: (1) develop a new neurobehavioral model of (chronic) depression (anhedonic behavior) that may reflect chronic LPS stimulation and is associated with increased oxidative stress, and (2) to delineate the effects of fluoxetine on this new depression model. We established that in female mice repeated LPS injections once daily for 5 days (from 750 μg/kg to a maximal dose 1250 μg/kg; increasing doses for the first three days which were then gradually decreased on day 4 and 5) at a one-month interval and this repeated for 4 consecutive months induced chronic anhedonia (estimated by the preference to drink a 1% sucrose) lasting for at least 7 weeks. Chronic LPS administration significantly decreased thymus weight, proliferative activity of splenocytes, production of interferon (IFN)γ and interleukin-(IL)10, and increased superoxide and corticosterone production. Treatment with fluoxetine for 3 weeks abolished the neurobehavioral effects of LPS. The antidepressant effect of fluoxetine was accompanied by increased production of IL-10 and reduced superoxide and corticosterone production. Our results suggest that repeated intermittent LPS injections to female mice may be a useful model of chronic depression and in particular for the depressogenic effects of long standing activation of the toll-like receptor IV complex.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313516     DOI: 10.1016/j.bbi.2013.01.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  27 in total

Review 1.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

2.  Sex differences in motivational responses to dietary fat in Syrian hamsters.

Authors:  John L Shannonhouse; Danielle M Grater; Daniel York; Paul J Wellman; Caurnel Morgan
Journal:  Physiol Behav       Date:  2015-04-18

3.  Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present.

Authors:  Denitsa Simeonova; Drozdstoy Stoyanov; Jean-Claude Leunis; Andre F Carvalho; Marta Kubera; Marianna Murdjeva; Michael Maes
Journal:  Neurotox Res       Date:  2019-12-04       Impact factor: 3.911

Review 4.  Rodent models of treatment-resistant depression.

Authors:  Barbara J Caldarone; Venetia Zachariou; Sarah L King
Journal:  Eur J Pharmacol       Date:  2014-11-21       Impact factor: 4.432

5.  Hangover Symptoms, Heavy Episodic Drinking, and Depression in Young Adults: A Cross-Lagged Analysis.

Authors:  Thomas M Piasecki; Constantine J Trela; Robin J Mermelstein
Journal:  J Stud Alcohol Drugs       Date:  2017-07       Impact factor: 2.582

6.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

7.  Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.

Authors:  Saritha Krishna; Celia A Dodd; Nikolay M Filipov
Journal:  Behav Brain Res       Date:  2016-01-21       Impact factor: 3.332

Review 8.  Role of neuro-immunological factors in the pathophysiology of mood disorders.

Authors:  Anindya Bhattacharya; Noel C Derecki; Timothy W Lovenberg; Wayne C Drevets
Journal:  Psychopharmacology (Berl)       Date:  2016-01-23       Impact factor: 4.530

9.  Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias.

Authors:  Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2013-04-30       Impact factor: 7.217

Review 10.  Molecular insights into the therapeutic promise of targeting HMGB1 in depression.

Authors:  Tarapati Rana; Tapan Behl; Vineet Mehta; Md Sahab Uddin; Simona Bungau
Journal:  Pharmacol Rep       Date:  2020-10-04       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.